Proteasome Inhibition Reprograms Chromatin Landscape in Breast Cancer

Area of Science:

• Cancer Biology
• Molecular Biology
• Genomics

Background:

• The 26S proteasome is crucial for protein degradation in cells.
• Cancer cells exploit proteasome function to regulate gene expression and promote tumor growth.
• Proteasome inhibitors are cancer therapeutics, but their precise mechanisms are not fully understood.

Purpose of the Study:

• To investigate the mechanistic effects of proteasome inhibitors on chromatin landscape and transcription in breast cancer.
• To identify specific genomic regions and transcriptional changes induced by proteasome inhibition.

Main Methods:

• Integrative genomic analysis of breast cancer cells treated with the proteasome inhibitor MG132.
• Analysis of chromatin accessibility and RNA polymerase II (RNAPII) transcription initiation.

Main Results:

• Discovered dynamic changes in chromatin accessibility, termed differentially open chromatin regions (DOCRs).
• Identified promoter-proximal DOCRs with decreased accessibility linked to divergent RNAPII transcription.
• Found distal DOCRs with increased accessibility enriched in oncogenic superenhancers, prevalent in non-basal breast cancer subtypes.

Conclusions:

• Proteasome inhibition causes significant reprogramming of the chromatin landscape and RNAPII transcription initiation in breast cancer cells.
• The study elucidates mechanisms by which proteasome inhibitors modulate gene networks critical for breast cancer biology.
• Findings highlight the role of altered chromatin accessibility in proteasome inhibitor efficacy, especially in non-basal breast cancers.